MdxHealth (TM) : MDxHealth's ConfirmMDx(TM) Test Outperforms PSA in Prostate Cancer Detection Algorithm and Decision for Repeat

 MdxHealth (TM) : MDxHealth's ConfirmMDx(TM) Test Outperforms PSA in Prostate
          Cancer Detection Algorithm and Decision for Repeat Biopsy

  Presentations at 2013 American Urology Association Annual Meeting Discuss
  How ConfirmMDx for Prostate Cancer and Detection Algorithm Helps Men Avoid
                                 Unnecessary
  Repeat Prostate Biopsies and Aid Urologists to Improve Patient Management

IRVINE, CA, and LIEGE, BELGIUM - 8:00 AM, April 22, 2013 - MDxHealth SA (NYSE
Euronext: MDXH), a leading molecular diagnostic company that develops and
commercializes epigenetic tests to support cancer treatment, today announced
two presentations on ConfirmMDx for Prostate Cancer, its test to help
urologists rule-out prostate cancer-free men from undergoing unnecessary
repeat biopsies, at the upcoming 2013 American Urology Association (AUA)
Annual Meeting in San Diego, CA (May 4-8, 2013). An abstract on the role of
ConfirmMDx has been chosen for the "Late-Breaking Science Forum" and key
urology experts will present data on the test as part of a panel discussion on
novel molecular biomarkers for prostate cancer.

"Late-Breaking Science Forum" Podium Presentation at AUA
In an oral presentation, Prof Wim Van Criekinge will describe how combining
the epigenetic ConfirmMDx for Prostate Cancer test with traditional
histopathological results and other risk factors, including PSA screening, was
shown to improve patient management by helping to stratify men who may avoid
unnecessary repeat biopsies from those who may harbor undetected prostate
cancer and who merit early repeat biopsy.

Title:       "A Model Combining Traditional Risk Factors with Epigenetic
              Profiling Avoids Unnecessary Repeat Biopsies"
Presentedby: Prof Wim Van Criekinge, Head of the Laboratory for Computational
              Genomics and Bioinformatics (Biobix), University of Ghent,
              Belgium
Date:         Tuesday, May 7th, 2013
Time:         1:00 - 2:30 pm
Location:     SDCC 6C, San Diego Convention Center

Clinical Update on Novel Prostate Cancer Biomarkers
Experts in the field of urology, Dr. David Crawford and Dr. Neal Shore will
discuss the role new molecular biomarkers, such as MDxHealth's ConfirmMDx and
Genomic Health's Oncotype DX, will play in the diagnosis and staging of
prostate cancer. The program is supported by the Prostate Conditions Education
Council, a consortium of leading physicians, health educators, scientists and
prostate cancer advocates, and is intended to outline the clinical utility of
these new molecular tests and how they will aid in the improved detection and
treatment of prostate cancer.

Title:        "Understanding How New Biomarkers Will Assist in the Diagnosis
              and Prognosis of Prostate Cancer"
Presentedby: E. David Crawford, M.D., Head Section of Urologic Oncology,
              Professor of Urology, Surgery and Radiation Oncology, University
              of Colorado School of Medicine, Denver, Colorado Neal D. Shore,
              M.D., FACS, Director, CPI, Carolina Urologic Research Center,
              Grand Strand Urology/Atlantic Urology Clinics, Myrtle Beach,
              South Carolina
Date:         Tuesday, May 7th, 2013
Time:         10 am
Location:     Industry Theatre, Exhibit Hall, San Diego Convention Center

About ConfirmMDx for Prostate Cancer
Over 650,000 American men receive a negative prostate biopsy result each year;
though approximately 25% of these men may still harbor occult prostate cancer.
This well-documented risk of undetected cancer, often with clinically
significant Gleason scores, leads to a high rate of repeat biopsies with over
40% of men receiving at least one repeat biopsy, and many receiving a 3^rd and
4^th biopsy. Today's gold standard diagnostic approach is the prostate biopsy
procedure, collecting 10-12 needle core biopsy samples, however this sampling
represents less than 1% of a man's prostate. ConfirmMDx for Prostate Cancer is
an epigenetic assay to help urologists distinguish patients who have a
true-negative biopsy from those at risk for occult cancer. The test is able to
detect an epigenetic field effect or "halo" associated with the cancerization
process at the DNA level. This molecular "halo" around a cancer lesion can be
present despite having a normal appearance under the microscope. The test
helps urologists rule out prostate cancer-free men from undergoing unnecessary
repeat biopsies and, helps rule in high risk patients who may require repeat
biopsies and potential treatment.

About MDxHealth
MDxHealth is a molecular diagnostics company that develops and commercializes
advanced epigenetic tests for cancer assessment and the personalized treatment
of patients. The company's first commercial product, ConfirmMDx^TM for
Prostate Cancer, has been shown to help distinguish patients who have a
true-negative biopsy from those who may have undetected cancer. MDxHealth
helps to address a large and growing unmet medical need for better cancer
diagnosis and treatment information. The company has a proprietary platform
and a strong epigenetic product pipeline focused on the development of
products for prostate, brain and lung cancers. The company is based in Irvine,
California with a European headquarters in Liege, Belgium. For more
information visit MDxHealth's website at www.mdxhealth.com.

For more information:
Dr Jan Groen
President and CEO      Mike Sinclair         Seth Lewis
MDxHealth              Halsin Partners       The Trout Group
US: +1 949 812 6979   UK: +44 20 7318 2955 US: +1 646 378 2952
BE: +32 4 364 20 70    Cell: +44 7968 022075 slewis@troutgroup.com
info@mdxhealth.com     msinclair@halsin.com

This press  release contains  forward-looking  statements and  estimates  with 
respect to the anticipated future performance  of MDxHealth and the market  in 
which it operates. Such statements and estimates are based on assumptions  and 
assessments of known and unknown risks, uncertainties and other factors, which
were deemed reasonable  but may  not prove to  be correct.  Actual events  are 
difficult to predict, may  depend upon factors that  are beyond the  company's 
control, and  may turn  out to  be materially  different. MDxHealth  expressly 
disclaims any obligation to update any such forward-looking statements in this
release to reflect any change in  its expectations with regard thereto or  any 
change in events, conditions or circumstances  on which any such statement  is 
based unless  required by  law or  regulation. This  press release  does  not 
constitute an offer or  invitation for the sale  or purchase of securities  or 
assets of MDxHealth  in any jurisdiction.  No securities of  MDxHealth may  be 
offered or sold within the United  States without registration under the  U.S. 
Securities Act  of  1933, as  amended,  or  in compliance  with  an  exemption 
therefrom, and in accordance with any applicable U.S. securities laws.

NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx and PredictMDx are  trademarks 
or registered trademarks  of MDxHealth  SA. All other  trademarks and  service 
marks are the property of their respective owners.

Clik here to access the PDF version

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: MdxHealth (TM) via Thomson Reuters ONE
HUG#1694495
 
Press spacebar to pause and continue. Press esc to stop.